The effect of acute exogenous melatonin on P50 suppression in healthy male volunteers stratified for low and high gating levels

Journal of Psychopharmacology

Volumn 26, Issue 8, 2012, Pages 1113-1118

  Ucar, Ebru ^a,b   Lehtinen, Emilia K ^a,b   Glenthøj, Birte Y ^a,c   Oranje, Bob ^a,c  

^a Mental Health Services CPH   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Healthy volunteers; melatonin; P50 suppression; schizophrenia; sensory gating

Indexed keywords

MELATONIN; PLACEBO;

ADULT; ALERTNESS; ARTICLE; AUDITORY STIMULATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; ELECTROCARDIOGRAM; HUMAN; HUMAN EXPERIMENT; MALE; MORNING DOSAGE; NORMAL HUMAN; P50 WAVE SUPPRESSION; PRIORITY JOURNAL; SENSORY GATING; VISUAL ANALOG SCALE;

ACOUSTIC STIMULATION; ADULT; AROUSAL; BRAIN WAVES; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ELECTROENCEPHALOGRAPHY; EVOKED POTENTIALS, AUDITORY; HUMANS; MALE; MELATONIN; SENSORY GATING;

EID: 84864124405     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881111430752     Document Type: Article

References (57)

1. Adler LE, Pachtman E, Franks RD, Pecevich M, Waldo MC, Freedman R. Neurophysiological evidence for a defect in neuronal mechanisms involved in sensory gating in schizophrenia. Biol Psychiatry. 1982 ; 17: 639-654
2. Adler LE, Hoffer LJ, Griffith J, Waldo MC, Freedman R. Normalization by nicotine of deficient auditory sensory gating in the relatives of schizophrenics. Biol Psychiatry. 1992 ; 32: 607-616
3. Adler LE, Hoffer LD, Wiser A, Freedman R. Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am J Psychiatry. 1993 ; 150: 1856-1861
4. Aggernaes B, Glenthoj BY, Ebdrup BH, Rasmussen H, Lublin H, Oranje B. Sensorimotor gating and habituation in antipsychotic-naive, first-episode schizophrenia patients before and after 6 months' treatment with quetiapine. Int J Neuropsychopharmacol. 2010 ; 13: 1383-1395
5. Bak N, Glenthoj BY, Rostrup E, Larsson HB, Oranje B. Source localization of sensory gating: a combined EEG and fMRI study in healthy volunteers. Neuroimage. 2011 ; 54: 2711-2718
6. Bersani G, Mameli M, Garavini A, Pancheri P, Nordio M. Reduction of night/day difference in melatonin blood levels as a possible disease-related index in schizophrenia. Neuro Endocrinol Lett. 2003 ; 24: 181-184
7. Binfare RW, Mantovani M, Budni J, Santos AR, Rodrigues AL. Involvement of dopamine receptors in the antidepressant-like effect of melatonin in the tail suspension test. Eur J Pharmacol. 2010 ; 638: 78-83
8. Bleuler E Dementia Precox or the Group of Schizophrenias. New York: International Universities Press ; 1911 :
9. Bond A, Lader M. The use of analogue scales in rating subjective feelings. Br J Med Psychol. 1974 ; 47: 211-218
10. Boutros NN, Zouridakis G, Overall J. Replication and extension of P50 findings in schizophrenia. Clin Electroencephalogr. 1991 ; 22: 40-45
11. Chemerinski E, Ho BC, Flaum M, Arndt S, Fleming F, Andreasen NC. Insomnia as a predictor for symptom worsening following antipsychotic withdrawal in schizophrenia. Compr Psychiatry. 2002 ; 43: 393-396
12. Clementz BA, Geyer MA, Braff DL. P50 suppression among schizophrenia and normal comparison subjects: a methodological analysis. Biol Psychiatry. 1997 ; 41: 1035-1044
13. Cohrs S. Sleep disturbances in patients with schizophrenia: impact and effect of antipsychotics. CNS Drugs. 2008 ; 22: 939-962
14. Croft RJ., Dimoska A, Gonsalvez CJ, Clarke AR. Suppression of P50 evoked potential component, schizotypal beliefs and smoking. Psychiatry Res. 2004 ; 128: 53-62
15. Csomor PA, Stadler RR, Feldon J, Yee BK, Geyer MA, Vollenweider FX. Haloperidol differentially modulates prepulse inhibition and p50 suppression in healthy humans stratified for low and high gating levels. Neuropsychopharmacology. 2008 ; 33: 497-512
16. Cullum CM, Harris JG, Waldo MC, Smernoff E, Madison A, Nagamoto HT, et al. Neurophysiological and neuropsychological evidence for attentional dysfunction in schizophrenia. Schizophr Res. 1993 ; 10: 131-141
17. Fanget F, Claustrat B, Dalery J, Brun J, Terra JL, Marie-Cardine M, et al. Nocturnal plasma melatonin levels in schizophrenic patients. Biol Psychiatry. 1989 ; 25: 499-501
18. Ferrier IN, Arendt J, Johnstone EC, Crow TJ. Reduced nocturnal melatonin secretion in chronic schizophrenia: relationship to body weight. Clin Endocrinol (Oxf). 1982 ; 17: 181-187
19. Freedman R, Adler LE, Waldo MC, Pachtman E, Franks RD. Neurophysiological evidence for a defect in inhibitory pathways in schizophrenia: comparison of medicated and drug-free patients. Biol Psychiatry. 1983 ; 18: 537-551
20. Geyer MA, Braff DL. Habituation of the Blink reflex in normals and schizophrenic patients. Psychophysiology. 1982 ; 19: 1-6
21. Geyer MA, Braff DL. Startle habituation and sensorimotor gating in schizophrenia and related animal models. Schizophr Bull. 1987 ; 13: 643-668
22. Griffith JM, Waldo M, Adler LE, Freedman R. Normalization of auditory sensory gating in schizophrenic patients after a brief period for sleep. Psychiatry Res. 1993 ; 49: 29-39
23. Ille N, Berg P, Scherg M. Artifact correction of the ongoing EEG using spatial filters based on artifact and brain signal topographies. J Clin Neurophysiol. 2002 ; 19: 113-124
24. Jensen KS, Oranje B, Wienberg M, Glenthoj BY. The effects of increased serotonergic activity on human sensory gating and its neural generators. Psychopharmacology (Berl). 2008 ; 196: 631-641
25. Kayumov L, Brown G, Jindal R, Buttoo K, Shapiro CM. A randomized, double-blind, placebo-controlled crossover study of the effect of exogenous melatonin on delayed sleep phase syndrome. Psychosom Med. 2001 ; 63: 40-48
26. Knott V, Millar A, Fisher D. Sensory gating and source analysis of the auditory P50 in low and high suppressors. Neuroimage. 2009 ; 44: 992-1000
27. Krystal AD, Goforth HW, Roth T. Effects of antipsychotic medications on sleep in schizophrenia. Int Clin Psychopharmacol. 2008 ; 23: 150-160
28. Lehtinen EK, Ucar E, Glenthøj BY, Oranje B. The effects of acute exogenous melatonin on human sensorimotor gating, habituation and sensitization. Submitted.. 2011 ;:
29. Lieberman JA, Sheitman BB, Kinon BJ. Neurochemical sensitization in the pathophysiology of schizophrenia: deficits and dysfunction in neuronal regulation and plasticity. Neuropsychopharmacology. 1997 ; 17: 205-229
30. Light GA, Braff DL. Human and animal studies of schizophrenia-related gating deficits. Curr Psychiatry Rep. 1999 ; 1: 31-40
31. Markus RP, Zago WM, Carneiro RC. Melatonin modulation of presynaptic nicotinic acetylcholine receptors in the rat vas deferens. J Pharmacol Exp Ther. 1996 ; 279: 18-22
32. Markus RP, Santos JM, Zago W, Reno LA. Melatonin nocturnal surge modulates nicotinic receptors and nicotine-induced [3H]glutamate release in rat cerebellum slices. J Pharmacol Exp Ther. 2003 ; 305: 525-530
33. McGhie A, Chapman J. Disorders of attention and perception in early schizophrenia. Br J Med Psychol. 1961 ; 34: 103-116
34. Monteleone P, Maj M, Fusco M, Kemali D, Reiter RJ. Depressed nocturnal plasma melatonin levels in drug-free paranoid schizophrenics. Schizophr Res. 1992 ; 7: 77-84
35. Monteleone P, Natale M, La RA, Maj M. Decreased nocturnal secretion of melatonin in drug-free schizophrenics: no change after subchronic treatment with antipsychotics. Neuropsychobiology. 1997 ; 36: 159-163
36. Nagamoto HT, Adler LE, Waldo MC, Freedman R. Sensory gating in schizophrenics and normal controls: effects of changing stimulation interval. Biol Psychiatry. 1989 ; 25: 549-561
37. Nagamoto HT, Adler LE, Waldo MC, Griffith J, Freedman R. Gating of auditory response in schizophrenics and normal controls. Effects of recording site and stimulation interval on the P50 wave. Schizophr Res. 1991 ; 4: 31-40
38. Oranje B, Jensen K, Wienberg M, Glenthoj BY. Divergent effects of increased serotonergic activity on psychophysiological parameters of human attention. Int J Neuropsychopharmacol. 2008 ; 11: 453-463
39. Pacchierotti C, Iapichino S, Bossini L, Pieraccini F, Castrogiovanni P. Melatonin in psychiatric disorders: a review on the melatonin involvement in psychiatry. Front Neuroendocrinol. 2001 ; 22: 18-32
40. Robinson S, Rosca P, Durst R, Shai U, Ghinea C, Schmidt U, et al. Serum melatonin levels in schizophrenic and schizoaffective hospitalized patients. Acta Psychiatr Scand. 1991 ; 84: 221-224
41. Schiller ED, Champney TH, Reiter CK, Dohrman DP. Melatonin inhibition of nicotine-stimulated dopamine release in PC12 cells. Brain Res. 2003 ; 966: 95-102
42. Schwarzkopf SB, Lamberti JS, Smith DA. Concurrent assessment of acoustic startle and auditory P50 evoked potential measures of sensory inhibition. Biol Psychiatry. 1993 ; 33: 815-828
43. Shamir E, Laudon M, Barak Y, Anis Y, Rotenberg V, Elizur A, et al. Melatonin improves sleep quality of patients with chronic schizophrenia. J Clin Psychiatry. 2000 ; 61: 373-377
44. Srinivasan V, Pandi-Perumal SR, Trakht I, Spence DW, Hardeland R, Poeggeler B, et al. Pathophysiology of depression: role of sleep and the melatonergic system. Psychiatry Res. 2009 ; 165: 201-214
45. Strother WN, Norman AB, Lehman MN. D1-dopamine receptor binding and tyrosine hydroxylase-immunoreactivity in the fetal and neonatal hamster suprachiasmatic nucleus. Brain Res Dev Brain Res. 1998 ; 106: 137-144
46. Suresh Kumar PN, Andrade C, Bhakta SG, Singh NM. Melatonin in schizophrenic outpatients with insomnia: a double-blind, placebo-controlled study. J Clin Psychiatry. 2007 ; 68: 237-241
47. Van Luijtelaar G. The effects of diazepam on sensory gating in healthy volunteers. Neurosci Lett. 2003 ; 341: 65-68
48. Vigano D, Lissoni P, Rovelli F, Roselli MG, Malugani F, Gavazzeni C, et al. A study of light/dark rhythm of melatonin in relation to cortisol and prolactin secretion in schizophrenia. Neuro Endocrinol Lett. 2001 ; 22: 137-141
49. Viswanathan N, Weaver DR, Reppert SM, Davis FC. Entrainment of the fetal hamster circadian pacemaker by prenatal injections of the dopamine agonist SKF 38393. J Neurosci. 1994 ; 14: 5393-5398
50. Wade AG, Crawford G, Ford I, McConnachie A, Nir T, Laudon M, et al. Prolonged release melatonin in the treatment of primary insomnia: evaluation of the age cut-off for short- and long-term response. Curr Med Res Opin. 2011 ; 27: 87-98
51. Ward PB, Hoffer LD, Liebert BJ, Catts SV, O'Donnell M, Adler LE. Replication of a P50 auditory gating deficit in Australian patients with schizophrenia. Psychiatry Res. 1996 ; 64: 121-135
52. Webb SM, Puig-Domingo M. Role of melatonin in health and disease. Clin Endocrinol (Oxf). 1995 ; 42: 221-234
53. Weinberger DR. The biological basis of schizophrenia: new directions. J Clin Psychiatry. 1997 ; 58 (Suppl 10). 22-27
54. Wing JK, Babor T, Brugha T, Burke J, Cooper JE, Giel R, et al. SCAN. Schedules for Clinical Assessment in Neuropsychiatry. Arch Gen Psychiatry. 1990 ; 47: 589-593
55. Yee CM, White PM. Experimental modification of P50 suppression. Psychophysiology. 2001 ; 38: 531-539
56. Yousaf F, Seet E, Venkatraghavan L, Abrishami A, Chung F. Efficacy and safety of melatonin as an anxiolytic and analgesic in the perioperative period: a qualitative systematic review of randomized trials. Anesthesiology. 2010 ; 113: 968-976
57. Zago WM, Markus RP. Melatonin modulation of presynaptic nicotinic acetylcholine receptors located on short noradrenergic neurons of the rat vas deferens: a pharmacological characterization. Braz J Med Biol Res. 1999 ; 32: 999-1006